Tag: US generics market
GENERAL Aurobindo Eyes $494-Mn US Market With Launch Of Tofacitinib Generic

Aurobindo Pharma has strengthened its presence in the lucrative US generics market after receiving final approval from the US Food and Drug Administration (USFDA) for Tofacitinib tablets in 5 mg and 10 mg strengths, opening the door to a market worth nearly $500 million annually. The approval allows the company to manufacture and market a […]

CW Bureau · Jun 4, 2026
GENERAL Aurobindo Pharma Gets USFDA Nod For Dapagliflozin-Metformin Combo

Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride extended-release tablets in multiple strengths such as 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg. The approved formulation is bioequivalent and therapeutically equivalent to the reference listed […]

CW Bureau · Apr 7, 2026